Abstract

Epilepsy remains a profound clinical challenge, with approximately one-third of patients exhibiting resistance to current antiseizure medications (ASMs). This persistent drug resistance highlights the limitations of traditional ion-channel targets and underscores an urgent need for alternative, mechanism-based neuromodulatory strategies. This review synthesizes current findings on the therapeutic potential of the noradrenergic system, specifically the -adrenergic receptor ( -AR), as a modulator of network excitability. We examine the biology of the -AR, which acts as a presynaptic "brake" on glutamatergic transmission, and review preclinical evidence evaluating brimonidine (UK14,304) as a prototype agonist. Emerging data suggest that selective -activation offers a state-dependent antiseizure mechanism, thereby suppressing pathological hypersynchrony while sparing physiological transmission. Finally, we propose that future therapeutic success depends upon the development of biased ligands and focal delivery systems, which may effectively harness -AR signaling to suppress focal seizures and mitigate the risk of Sudden Unexpected Death in Epilepsy (SUDEP).